Home › Companies › FBIO

Fortress Biotech

Market cap $61.4M 33.7M shares (vendor count, Nov 18, 2026) × $1.82 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-03-31

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. ATX-04 clenbuterol trial start2026ATX-04 clenbuterol trial start, 2026, routine
  2. Dotinurad Ph3 toplineLate 2026Dotinurad Ph3 topline, Late 2026, material
  3. Triplex Ph2 readoutEnd of 2026Triplex Ph2 readout, End of 2026, notable
  4. MB-109 Ph1 start1Q 2027MB-109 Ph1 start, 1Q 2027, routine
  5. S-3 shelf eligibility corporate updateMar 2027S-3 shelf eligibility corporate update, Mar 2027, routine
  6. FB-607 AcqCorpLXII Ph2 topline2H 2027FB-607 AcqCorpLXII Ph2 topline, 2H 2027, material
  7. Oaktree debt corporate updateJun 2028Oaktree debt corporate update, Jun 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (16 active programs)

Emrosi

minocycline hydrochloride extended-release capsules · Minocycline Hydrochloride Modified Release Capsules · DFD-29

Discontinued (1)

Capital (as filed)

Cash
$152M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$6.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$114M cash per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Fortress Biotech, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Fortress Biotech (FBIO): Scientific Deep Dive for Lead and Pipeline Products The ZYCUBO PRV sale buys Fortress survival but the corporate structure's relentless dilution of common shareholders via subsidiary fees and preferred dividend arrears demands extreme caution before initiating a position.
  2. Watch speculative UPDATE: Fortress Biotech (FBIO) - The PRV Cash Lands, The Covenants Vanish, The Stock Bleeds Anyway The corporate de-risking thesis has been validated — PRV monetized, Oaktree covenants disarmed, Emrosi ramping — and the 29% stock decline since the deep dive creates a speculative entry opportunity for deep-value arbitrageurs willing to wait for capital structure cleanup.
  3. Speculative buy speculative UPDATE: Fortress Biotech (FBIO) - Journey Hits Positive EBITDA, Emrosi Triples YoY Journey Medical's first positive Adjusted EBITDA quarter and Emrosi's 3x YoY revenue ramp confirm the commercial leg of the sum-of-the-parts thesis, though the preferred dividend arrears remain the unaddressed bear catalyst.
  4. Speculative buy speculative UPDATE: Fortress Biotech (FBIO) - The Parent Balance Sheet Finally Prints The Q1 10-Q reveals $209.9M of parent-level cash against a ~$76M market cap and $15M of recourse debt with disarmed covenants, making the price-to-book discount wider than ever, but the $14M preferred arrears remain unaddressed and the S-3 shelf stays locked.
  5. Speculative buy speculative UPDATE: Fortress Biotech (FBIO) - The Free Option Just Got Funded Crystalys closing an oversubscribed $130M Series B validates the dotinurad free option thesis with $335M of third-party capital now behind the asset, while the stock's 42% move has partially closed the discount but the preferred arrears remain unaddressed.
  6. Speculative buy speculative UPDATE: Fortress Biotech (FBIO) - The Spoke Keeps Printing, The Hub Keeps Discounting Journey's Q2 print of $8.1M Emrosi revenue and +$2.9M Adjusted EBITDA confirms the commercial spoke is self-funding, but the 15.9% pullback from the Crystalys pop and the still-unaddressed $14M preferred arrears keep the discount open.
  7. Speculative buy speculative UPDATE: Fortress Biotech (FBIO) - The Three Lines I Was Watching All Printed The Q2 10-Q confirms Crystalys marked up to $26.9M, $95.4M Cyprium dividend in transit to the parent, and book value of $164.1M against a ~$99M market cap, but preferred arrears grew to $16.0M for the fifth consecutive quarter with no action from management.
  8. Watch UPDATE: Fortress Biotech (FBIO) - The Lender Got Paid. The Deadline Passed. The Q3 deadline the author set in April for management to address preferred arrears expired without action; Fortress paid off the Oaktree lender instead, so the downgrade to Watch List is triggered despite the parent now being debt-free and trading below cash.
  9. Avoid UPDATE: Fortress Biotech (FBIO) - The Test I Set Has Been Graded The Q3 10-Q confirms $18.1M of preferred arrears and $114.1M of parent cash — exactly meeting the author's stated bear-case threshold — while management launched a new encumbered subsidiary (FB-607) instead of clearing the arrears, proving the governance thesis wrong.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

3 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)